Announces two new in-house discovered assets - ATG-031, a potential first-in-class anti-CD24 monoclonal antibody, and ATG-027, a potential first-in-class B7H3/PD-L1 bi-specific antibody Provides an update on commercial readiness across the Asia Pacific markets for selinexor, Antengene's...
from PR Newswire: https://ift.tt/2UhfF3S
No comments:
Post a Comment